Abstract:Phenytoin is a well-known anticonvulsant medication that is useful in the management of most seizure disorders. Given the narrow therapeutic index of 10-20 mg/mL, acute phenytoin overdose can occur with either oral or intravenous administration. There is no distinct antidote to phenytoin, and therefore supportive care is the treatment of choice. Various methods to enhance the elimination have been discussed controversially and have shown a limited effect. We discuss a case in which intermittent hemodialysis was shown to significantly enhance the elimination of phenytoin in an acute overdose and drastically improve the clinical outcome. A 46-year-old male presented to the emergency department after a fall in which he injured his head and left knee. The patient admitted to ingesting 60 tablets of 100 mg extended-release phenytoin directly preceding the fall. He presented lethargic with slurred speech and ataxia. The patient was admitted to the ICU for observation with an initial phenytoin level of 50.1 mg/L. Phenytoin levels peaked at 68.7 mg/L on day two and continued to fluctuate. On day seven of admission, the level remained high at 62.6 mg/L, and at this point, the hospitalist, nephrologist, and poison control agreed to proceed with a trial of intermittent hemodialysis. After a four-hour dialysis session, phenytoin levels declined 27% to 45.6 mg/L and continued to fall. The patient's symptoms of slurred speech, drowsiness, and agitation remained throughout the hospital course but improved each day after hemodialysis. Phenytoin levels reached a therapeutic level of 19.5 mg/L on day 14 of admission, and the patient was alert, talkative, and asymptomatic. Intermittent hemodialysis was shown to be an effective elimination method in those with severe phenytoin toxicity and should be considered as a therapeutic option. Even with significant albumin binding, a single session of hemodialysis lowered the phenytoin levels by 27%. We also suspect the removal of additional toxins, and the desaturation of hepatic metabolism could have aided in the patient's clinical improvement, further supporting therapeutic hemodialysis.

'Double whammy': An Unusual Co-occurrence of Idiosyncratic phenytoin–induced agranulocytosis and acute liver failure in a pediatric patient

The Phenytoin Ataxia Enigma Unveiled ''A Case Report''

A Rare Case of Hemodialysis as an Extracorporeal Treatment for Severe Phenytoin Overdose

Acute Severe Pancreatitis: A Dreadful Complication of Sodium Valproate

[Valproic Acid-Induced Idiosyncratic Liver Injury in 4 Cases].

Unusual Synchronous Methimazole-Induced Agranulocytosis And Severe Hepatotoxicity In Patient With Hyperthyroidism: A Case Report And Review Of The Literature

Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury

Drug-induced hypersensitivity syndrome due to phenytoin: Case report and review of the literature

Fatal carboplatin-induced immune hemolytic anemia in a child with a brain tumor

Phenobarbital induced leucopenia in a child with epilepsy

Type 1 Diabetes Mellitus in a Child with Phenobarbital Hypersensitivity Syndrome

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report

Patient resuscitated after cardiopulmonary arrest exhibits abnormally increased phenytoin metabolic rate due to unknown factors: a case report

Phenytoin in treatment of amiodarone-induced Torsades de pointes

Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion

Assessing risk factors associated with breakthrough early post-traumatic seizures in patients receiving phenytoin prophylaxis

Neuroleptic malignant-like syndrome causing thrombocytopaenia: a rare association

A Case of Severe Thrombocytopenia, Aseptic Meningitis, and Hepatitis Caused by Trimethoprim-Sulfamethoxazole: A Triple Threat

Early-Onset Epileptic Encephalopathy Responsive to Phenytoin: A Diagnostic Clue for Fibroblast Growth Factor 12 Mutation

Pyridoxine-responsive KCNQ2 epileptic encephalopathy: Additional cases and literature review

The first reported case of concurrent trimethoprim-sulfamethoxazole-induced immune hemolytic anemia and thrombocytopenia